Posted by Michael Wonder on 19 Sep 2020
US FDA grants once daily dosing option for Nityr (nitisinone) tablets for HT-1 patients
14 September 2020 - Cycle Pharmaceuticals is pleased to announce that the U.S. FDA has approved the once daily dosing of Nityr.
This dosing regimen is now an option for patients 5 years of age and older who have undetectable serum and urine succinylacetone concentrations after a minimum of 4 weeks on a stable dosage of nitisinone.
Nityr is indicated for the treatment of patients with hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.
